http://www.fpnotebook.com/
ModafinilAka: Provigil
- Indications
- Narcolepsy
- Non-FDA approved use
- Attention Deficit Hyperactivity Disorder
- Fatigue in Multiple Sclerosis
- Excessive Sleepiness in myotonic dystrophy
- Contraindications (relative)
- Coronary Artery Disease
- Hypertension
- Other cardiovascular disease
- Mechanism
- Stimulant
- Dosing: Adults
- ADHD: 100-300 mg PO qd (Not FDA approved)
- Narcolepsy: 200 mg qAM
- Dosing: Children Age >5 years
- ADHD: 50-100 mg PO qd (Not FDA approved)
- Efficacy: Narcolepsy
- May be slightly less effective then agents above
- Less addictive potential then agents above
- (1999) Med Lett Drugs Ther 41(1049):30
- Efficacy: ADHD
- Only small studies to show effectiveness and safety
- References
- Adverse Effects
- Headache
- Nervousness
- Dizziness
- Depressed mood
- Anxiety
- Cataplexy
- Insomnia
- Diarrhea
- Nausea
- Xerostomia
- Anorexia
- Paresthesias
- Pharyngitis or Rhinitis
- References
- (2003) Lexi-Comp Drug Database for Pocket PC (7/9/03)
modafinil (C0066677) | |
|---|---|
| Definition (NCI) | A drug that is being studied as a treatment for fatigue in patients with cancer. It belongs to the family of drugs called stimulants. |
| Definition (PDQ) | A synthetic central nervous system stimulant with wakefulness-promoting activity. Modafinil appears to inhibit dopamine reuptake, resulting in an increase in extracellular dopamine. This agent exhibits pronounced wakefulness-promoting activity (without sympathomimetic activity) and may improve cognitive function in certain clinical settings. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=256449&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=256449&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26661" NCI Thesaurus) |
| Definition (NCI) | A synthetic central nervous system stimulant with wakefulness-promoting activity. Modafinil appears to inhibit dopamine reuptake, resulting in an increase in extracellular dopamine. This agent exhibits pronounced wakefulness-promoting activity (without sympathomimetic activity) and may improve cognitive function in certain clinical settings. (NCI04) |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C048833 |
| English | benzhydrylsulfinylacetamide, modafinil, MODAFINIL PREPARATION |
| Spanish | modafinil |
| Parent Concepts | Miscellaneous Adjuvant (C1513319), Benzhydryl Compounds (C0005046), Other central nervous system stimulants (C0731742), Central Nervous System Stimulants (C0002763), Analeptics (C0242181), Drug allergen (C1320237), Non-amphetamines (C1579270) |
| Sources | MSH, MTHSPL, NCI, NDFRT, PDQ, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Provigil (C0722882) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C048833 |
| English | Cephalon brand of modafinil, Provigil |
| Sources | MSH, NCI, PDQ, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
